284 related articles for article (PubMed ID: 19743573)
1. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
[No Abstract] [Full Text] [Related]
2. Corticosteroids: no drug prevention of fractures needed.
Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide: new indication. Fracture prevention in men: no progress.
Prescrire Int; 2008 Oct; 17(97):194. PubMed ID: 19534046
[TBL] [Abstract][Full Text] [Related]
4. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
5. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
6. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
7. Treating osteoporosis with teriparatide: many unknowns?
Shukla VK
Issues Emerg Health Technol; 2003 Nov; (51):1-4. PubMed ID: 14610756
[TBL] [Abstract][Full Text] [Related]
8. Management of corticosteroid-induced osteoporosis.
Drug Ther Bull; 2010 Sep; 48(9):98-101. PubMed ID: 20810708
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide (forteo) for osteoporsis.
Med Lett Drugs Ther; 2003 Feb; 45(1149):9-10. PubMed ID: 12571538
[No Abstract] [Full Text] [Related]
12. Patient experience with a new teriparatide delivery device.
Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
[TBL] [Abstract][Full Text] [Related]
13. [Process in development of PTH, an awaited bone-density conservation agent].
Sugimoto T
Clin Calcium; 2012 Mar; 22(3):307. PubMed ID: 22893932
[No Abstract] [Full Text] [Related]
14. Corticosteroid osteoporosis: practical implications of recent trials.
Sambrook PN
J Bone Miner Res; 2000 Sep; 15(9):1645-9. PubMed ID: 10976984
[TBL] [Abstract][Full Text] [Related]
15. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
Endo I; Matsumoto T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
[No Abstract] [Full Text] [Related]
16. [New medication for osteoporosis. To further increase instead of braking reduction].
MMW Fortschr Med; 2003 Oct; 145(44):44. PubMed ID: 14655508
[No Abstract] [Full Text] [Related]
17. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Hodsman A; ; Papaioannou A; ; Ann Cranney ;
CMAJ; 2006 Jul; 175(1):48. PubMed ID: 16818909
[No Abstract] [Full Text] [Related]
18. [New therapeutic approach in glucocorticoid-induce osteoporosis].
Jakob F; Nitschmann S
Internist (Berl); 2008 Dec; 49(12):1524-5. PubMed ID: 19018505
[No Abstract] [Full Text] [Related]
19. Filling the gaps: osteogenesis imperfecta.
Graul AI
Drug News Perspect; 2005; 18(6):400-1. PubMed ID: 16247517
[No Abstract] [Full Text] [Related]
20. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
